Steven Alvarez-Mott, MD
Obstetrics/Gynecology · Glendora
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 43 years
- Irvine California College of Medicine, 1983
Offices
2 locations · Emanate Health Medical Care Foundation · 85 clinicians in this group
Looking this up.
Hospitals listed: Emanate Health Foothill Presbyterian Hospital · Emanate Health Inter-Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Alvarez-Mott’s office at (626) 963-4124 to ask if they take your plan before you enroll.
California Medical Board record
Licence G53551 · Current
Licensed to practise in California · since 1984 · expires 2028-03-31 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Glendora Surgery Center, Inc.Ambulatory Surgery Center · Glendora, CA1.23% owner since 2003 · accredited by AAAHCAccreditation Renewed6 inspections, 2 with deficiencies · last 2024-06-03: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Emanate Health Foothill Presbyterian HospitalGlendora, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency departmentPart of Emanate Health, which runs 3 hospitalsPatients rate it 2 of 5 · 63% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025
- Emanate Health Inter-Community HospitalCovina, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Emanate Health, which runs 3 hospitalsPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Emanate Health Foothill Presbyterian Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2) · 475 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.74 to 1.58) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.2 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 108 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 64 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.7 · 1,404 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.51) · 2,452 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.57 (1.08 to 6.06) · 286 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.51 (0.83 to 4.19) · 283 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.99 (1.35 to 20.62) · 77 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.86 (1.63 to 10.08) · 56 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.97 (0.06 to 1.88) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.662 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.026 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 44 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 234 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.2 · 139 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 308 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.1 · 520 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 85 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9 to 16.2) · 293 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 174 cases | No different | Jan 2024 – Dec 2024 |
What patients said (582 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 52% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 65% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Emanate Health Inter-Community Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 2 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.4 (0.39 to 2.4) · 990 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.53 to 1.18) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.56 (145.92 to 251.21) · 69 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 99 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.8 · 107 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 279 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 665 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.3 · 389 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.1 · 3,599 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.36) · 6,844 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.42) · 6,958 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.21 (0.98 to 5.43) · 1,118 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.46 (0 to 3.08) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (0.53 to 3.58) · 1,140 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.68 (1.69 to 15.67) · 450 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.07 (1.14 to 9) · 397 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.17) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 0.97) · 5,698 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 213 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.578 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.853 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.438 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.205 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 352 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.7 · 631 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2 · 136 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.5 · 336 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -2.2 · 731 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 1,007 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.5 to 8) · 53 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (8.8 to 16.5) · 53 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.4 · 191 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.6 to 17.6) · 113 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 106 cases | No different | Jan 2024 – Dec 2024 |
What patients said (924 patients answered, 12% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 77% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 77% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 66% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$8,338
Medicare paid this office $8,338 for 49 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 28 | $1,187 | $42 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 23 | $1,137 | $49 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
49 Original Medicare patients in 2024. Average age 66 · Under 65 29% · Women 100% · Also on Medicaid 71% · Health risk score 1.69. Sicker patients than 9 in 10 peers; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 71% · Diabetes 35% · Coronary heart disease 29% · Depression 24%.
The office billed $34,154, Medicare allowed $10,026 and paid $8,338; for 95 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 49 | 95 | 66 | 1.69 | $34,154 | $8,338 |
| 2023 | 61 | 103 | 65 | 1.88 | $37,269 | $9,926 |
| 2022 | 81 | 163 | 62 | 1.77 | $38,357 | $11,182 |
| 2021 | 68 | 139 | 62 | 1.89 | $33,357 | $9,328 |
| 2020 | 33 | 68 | 60 | 1.36 | $20,436 | $5,745 |
| 2019 | 116 | 220 | 63 | 1.99 | $45,545 | $19,785 |
| 2018 | 103 | 212 | 60 | 1.57 | $32,890 | $14,621 |
| 2017 | 107 | 218 | 60 | 1.99 | $37,210 | $15,704 |
| 2016 | 123 | 254 | 60 | 1.97 | $41,860 | $18,881 |
| 2015 | 142 | 305 | 60 | 1.78 | $45,196 | $23,921 |
| 2014 | 131 | 265 | 59 | 1.51 | $61,366 | $28,183 |
| 2013 | 111 | 212 | 59 | 1.85 | $37,359 | $16,891 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Short return visit (20+ min) | 19 | $1,604 | $70 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 18 | $898 | $50 |
2022: 2 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 54 | $2,638 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 53 | $2,306 | $44 |
2021: 3 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 43 | $2,126 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 43 | $1,886 | $44 |
| Short return visit (20+ min) | 14 | $1,183 | $79 |
2020: 2 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $544 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 11 | $493 | $45 |
2019: 4 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 23 | $2,942 | $128 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 58 | $2,832 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 58 | $2,486 | $43 |
| Short return visit (20+ min) | 18 | $1,874 | $55 |
2018: 4 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 59 | $2,857 | $48 |
| Short return visit (20+ min) | 26 | $2,611 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 59 | $2,399 | $41 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 17 | $2,124 | $125 |
2017: 4 services
| Short return visit (20+ min) | 35 | $3,196 | $54 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $2,959 | $123 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 43 | $2,090 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 43 | $1,762 | $41 |
2016: 4 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 31 | $3,837 | $124 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 56 | $2,738 | $49 |
| Short return visit (20+ min) | 31 | $2,526 | $52 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 57 | $2,332 | $41 |
2015: 5 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 75 | $3,709 | $49 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 29 | $3,643 | $126 |
| Short return visit (20+ min) | 30 | $3,343 | $59 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 76 | $3,145 | $41 |
| Complete ultrasound scan of pelvis | 13 | $1,269 | $98 |
2014: 5 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 32 | $3,916 | $122 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 50 | $2,445 | $49 |
| Short return visit (20+ min) | 30 | $2,444 | $56 |
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 14 | $2,096 | $150 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 51 | $2,084 | $41 |
2013: 5 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 28 | $3,385 | $121 |
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 15 | $2,323 | $155 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 43 | $2,163 | $50 |
| Short return visit (20+ min) | 21 | $1,869 | $58 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 43 | $1,766 | $41 |
Medicaid work
$1,063 in 2024
Medicaid paid $1,063 for 101 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 59 | $460 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 14 | $320 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation | 13 | $283 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $0 |
| 2024 | 101 | 4 | 17 | $1,063 |
| 2023 | 465 | 3 | 26 | $6,198 |
| 2022 | 486 | 6 | 29 | $8,641 |
| 2021 | 579 | 7 | 27 | $11,010 |
| 2020 | 381 | 4 | 31 | $9,504 |
| 2019 | 586 | 4 | 39 | $12,828 |
| 2018 | 582 | 6 | 51 | $21,858 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 194 | $3,707 |
| Short return visit (20+ min) | 186 | $2,411 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 85 | $80 |
2022
| Short return visit (20+ min) | 219 | $3,461 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 163 | $3,258 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation | 58 | $1,226 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 15 | $659 |
| Return visit (30+ min) | 18 | $38 |
| Cytopathology, slides, cervical or vaginal; manual screening under physician supervision | 13 | $0 |
2021
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation | 187 | $4,384 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 100 | $1,949 |
| Short return visit (20+ min) | 219 | $1,931 |
| Service | 29 | $1,578 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; single or first gestation | 17 | $594 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 15 | $573 |
| Cytopathology, slides, cervical or vaginal; manual screening under physician supervision | 12 | $0 |
2020
| OBSTETRICAL CARE | 13 | $5,813 |
| Short return visit (20+ min) | 244 | $1,621 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation | 93 | $1,486 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 31 | $584 |
2019
| Service | 176 | $9,667 |
| Short return visit (20+ min) | 318 | $2,253 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation | 63 | $909 |
| Cytopathology, slides, cervical or vaginal; manual screening under physician supervision | 29 | $0 |
2018
| Service | 269 | $14,730 |
| Short return visit (20+ min) | 191 | $3,540 |
| Service | 12 | $1,387 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 17 | $892 |
| New patient visit (45+ min) | 66 | $675 |
| New patient visit (30+ min) | 27 | $634 |
Drugs they prescribed that Part D paid
$20,860
Pharmacies billed $20,860 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
105 generic and 24 brand-name prescriptions · $20,860 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Orilissa | 13 | $17,032 | $1,310 |
| Estradiol | 23 | $513 | $22 |
| Alendronate | 16 | $37 | $2 |
Year by year
| 2024 | 129 | 48 | None | 19% | $20,860 |
| 2023 | 142 | 49 | None | 22% | $20,360 |
| 2022 | 121 | 45 | None | 15% | $16,961 |
| 2021 | 93 | 35 | None | 18% | $12,487 |
| 2020 | 112 | 36 | None | 17% | $17,303 |
| 2019 | 136 | 55 | 8% (11) | None | $5,517 |
| 2018 | 134 | 49 | None | 11% | $4,531 |
| 2017 | 89 | 39 | None | None | $3,513 |
| 2016 | 146 | 49 | 12% (17) | 12% | $6,266 |
| 2015 | 163 | 55 | 8% (13) | 12% | $6,695 |
| 2014 | 156 | 54 | 12% (19) | 12% | $5,804 |
| 2013 | 158 | 53 | None | None | $10,194 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Orilissa | 12 | $14,248 | $1,187 |
| Estradiol | 30 | $1,286 | $43 |
| Clindamycin Phosphate | 11 | $656 | $60 |
| Alendronate | 21 | $153 | $7 |
2022: 3 drugs
| Estradiol | 14 | $324 | $23 |
| Oxybutynin Chloride Er | 12 | $221 | $18 |
| Alendronate | 17 | $89 | $5 |
2021: 2 drugs
| Estradiol | 13 | $1,359 | $105 |
| Rosuvastatin | 11 | $762 | $69 |
2020: 1 drug
| Oxybutynin Chloride Er | 12 | $267 | $22 |
2019: 1 drug
| Oxybutynin Chloride Er | 13 | $290 | $22 |
2018: 3 drugs
| Oxybutynin Chloride Er | 12 | $318 | $27 |
| Nitrofurantoin Mono-Macro | 11 | $223 | $20 |
| Alendronate | 12 | $69 | $6 |
2017: 2 drugs
| Oxybutynin Chloride Er | 12 | $370 | $31 |
| Norgestimate-Ethinyl Estradiol | 12 | $108 | $9 |
2016: 7 drugs
| Clobetasol Propionate | 13 | $1,310 | $101 |
| Oxybutynin Chloride Er | 15 | $507 | $34 |
| Gildess | 12 | $287 | $24 |
| Estradiol | 14 | $232 | $17 |
| Medroxyprogesterone Acetate | 14 | $215 | $15 |
| Oxycodone-Acetaminophen | 16 | $161 | $10 |
| Norgestimate-Ethinyl Estradiol | 13 | $159 | $12 |
2015: 4 drugs
| Progesterone | 11 | $390 | $35 |
| Oxybutynin Chloride Er | 13 | $355 | $27 |
| Norgestimate-Ethinyl Estradiol | 18 | $285 | $16 |
| Oxycodone-Acetaminophen | 13 | $121 | $9 |
2014: 2 drugs
| Norgestimate-Ethinyl Estradiol | 13 | $256 | $20 |
| Buspirone | 12 | $84 | $7 |
2013: 2 drugs
| Ibandronate | 11 | $672 | $61 |
| Estradiol | 15 | $183 | $12 |
Money from drug and device companies
$39 in 2024
| 2024 | 1 | 1 | None | $39 |
| 2023 | 2 | 2 | None | $45 |
| 2022 | 1 | 1 | None | $18 |
| 2021 | 5 | 17 | None | $474 |
| 2020 | 3 | 3 | None | $85 |
| 2019 | 4 | 7 | None | $195 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abiomed | Impella | $39 | 1 payment
|
See the published payment
| Abiomed | Meals · 2024-07-26 | Impella | $39 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $45
| AbbVie | Orilissa | $26 | 1 payment
|
| Hologic Sales and Service | Acessa Provu System | $19 | 1 payment
|
2022: $18
| Abbvie | Lo Loestrin Fe | $18 | 1 payment
|
2021: $474
| AbbVie | Oriahnn | $385 | 12 payments
|
| Myovant Sciences | Myfembree | $28 | 2 payments
|
| Hologic | Novasure | $23 | 1 payment
|
| Ethicon US | Ethicon | $21 | 1 payment
|
| Pfizer | Premarin | $17 | 1 payment
|
2020: $85
| DySIS Medical | Ultra 2.0 | $42 | 1 payment
|
| Hologic | Novasure | $23 | 1 payment
|
| AbbVie | Oriahnn | $20 | 1 payment
|
2019: $195
| AbbVie | Orilissa | $132 | 2 payments
|
| Pfizer | Premarin | $31 | 2 payments
|
| Hologic | Novasure | $17 | 2 payments
|
| Minerva Surgical | Endometrial Ablation System (Device) | $14 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 79.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1659373850
- Licence
- CA G53551California G53551: Current · expires 2028-03-31
- Trained
- Irvine California College of Medicine, 1983 · 43 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G535510
- Taxonomy
- Federal specialty code 207V00000X (207V00000X); Federal specialty code 174400000X (174400000X)
- Mailing address
- 315 E Route 66, Ste 101, Glendora, CA, 91740
- NPI first listed
- 2005-06-01
- NPI last updated
- 2024-01-30
- NPI record certified
- 2024-01-30
This is when the NPI record was last certified, not a medical board exam.